Movetis Advances Cirrhosis Drug to Phase IIb Trial
Posted on: Friday, 4 July 2008, 12:00 CDT
Movetis has announced that M0002 is progressing to Phase IIb following positive results of a Phase IIa multiple-dosing trial for the treatment of ascites.
The randomized, double blind, placebo controlled, dose-titration study explored the safety, tolerability, pharmacokinetic profile and efficacy of M0002 in cirrhotic subjects with ascites and hypo- or normonatraemia. It was conducted in Belgium at multiple centers and enrolled 15 patients who were treated once daily with drug or placebo for 15 days.
Although a small number of patients were included in the study, a trend towards more stabilized and normalized plasma sodium levels was seen in those treated with M0002.
M0002 is an orally-active selective vasopressin 2 receptor antagonist and a member of a new class of compounds, known as aquaretics, which inhibit water reabsorption from the renal collecting duct.
Ascites is the accumulation of fluid in the abdomen in patients with liver cirrhosis resulting from liver conditions such as hepatitis C, hepatitis B or alcoholism.
Remi Broeck, chief development officer of Movetis, said: "We are delighted with the promising results from the dose-titration trial. We will begin patient recruitment shortly for a Phase IIb dose-finding study."
Source: Datamonitor
Related Articles
- Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
- Pacgen Announces Positive Results From Phase IIb Dose-Ranging Trial of PAC-113
- Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug
- Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
- Semafore and Multiple Myeloma Research Consortium (MMRC) Dose First Patient in Phase I Study of Targeted PI3 Kinase (PI3K) Inhibitor
- Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
- ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders
- INNOVIVE Pharmaceuticals Enrolls First Patients in Phase I Study of INNO-406 in CML
- MannKind Corporation Announces Positive Results From a Phase 2b Dose-Ranging Study of Technosphere(R) Insulin in Patients With Type 2 Diabetes
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
 |
 |
User Comments (0)
RSS Feeds